A COMPARISON OF SATB2 EXPRESSION RESULTS WITH CK20 AND CDX2 IN METASTATIC COLORECTAL CARCINOMA CASES

Zehra BoZdag1, ayse Nur akatli2

1Gaziantep University, Faculty of Medicine, Department of Pathology - 2Inonu University, Faculty of Medicine, Department of Pathology

 Introduction: SATB2 (The special AT-rich sequence-binding protein 2) is the new DNA binding protein and nuclear transcrip- tion factor. In normal epithelial tissues, the SATB2 protein is specifically expressed in the nuclei of the lower gastrointestinal (GI) tract epithelial cells. The elective expression of SATB2 in the lower GI tract implies that it can be used as a diagnostic marker for metastatic colorectal carcinoma (CRC).

Materials and methods: Immunohistochemical (IHC) analysis was performed by applying SATB2, CK20 and CDX2 in 96 meta- static CRC cases (51 liver, 22 lung, 19 ovarian, 3 skin and 1 uterine myometrial tissue) with various origins. The aim is to evaluate the diagnostic value of SATB2 alone, and the double and triple combinations of SATB2 with CK20 and CDX2.

Results: Out of 96 metastatic colon carcinoma cases, 94 (97.9%) had positive SATB2 expressions. It was found that 93.7% (90/96) of the cases had expression with CK 20 and CDX2. The sensitivity of SATB2 alone was 97.92%, and the sensitivity of CK20 and CDX2 alone was the same, i.e. 93.75%. This rate was also higher in the double combination of SATB2 with CDX2 and CK20 in comparison to the double combination of CK20 and CDX2. The sensitivity of SATB2 and CK20 combination was 98.8%, which was higher than that of CK20 and CDX2 combination.

Conclusions: Our results support the requirement of including SATB2 in the IHC panel for metastatic CRC cases.